[Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy].
Lebedeva
I V
IV
Department of Medicine and Pharmacology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.
Staĭn
S A
SA
D001483:Base Sequence; D019254:Genes, bcl-2; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D013489:Suppression, Genetic / Q000187:drug effects*; D051020:bcl-X Protein
C494811:BCL2L1 protein, human; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein